Skip to main content

Artelo Biosciences, Inc.

ARTL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001621221

No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Artelo Biosciences, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of ARTL: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders1722+5
Shares1.99M1.90M−86.4K (−4.4%)
Value$1.57M$984.0K−$585.0K (−37.3%)

New holders (8)

Institutions that held Artelo Biosciences, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to ARTL in Q4 2021
InstitutionSharesValue% of portfolio
Commonwealth Equity Services, LLC27,470$14.0K0.00%
Two Sigma Securities, LLC24,622$13.0K0.00%
Susquehanna International Group, LLP16,284$8.00K0.00%
Millennium Management LLC11,977$6.00K0.00%
State Street Corp10,400$5.00K0.00%
Creative Financial Designs Inc1,075$1.00K0.00%
Morgan Stanley2$00.00%
Global Wealth Management Investment Advisory, Inc.475$00.00%

Sold out (3)

Institutions that held Artelo Biosciences, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of ARTL in Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Boothbay Fund Management, LLC122,895$97.0K
LVM Capital Management Ltd12,000$9.00K
Advisor Group Holdings, Inc.35$0